论文部分内容阅读
Infliximab是抗肿瘤坏死因子α(TNFα)的人鼠嵌合单克隆抗体,可应用于对传统药物治疗无效的难治性克罗恩病,总有效率为65％～80％,于1998年获得美国食品和药品管理局通过,适宜于中重度克罗恩病和伴有瘘管的克罗恩病的治疗。但是Infliximab的疗效仅能维持2～3个月,停止治疗后疾病,易复发,故需采用间隔静脉注射的方法维持疗效,不过反复静脉注射不仅增加了患者的经济负担,而且还
Infliximab is a human and mouse chimeric monoclonal antibody against tumor necrosis factor alpha (TNFα), which can be applied to refractory Crohn’s disease that is refractory to conventional medical therapy with a total effective rate of 65% -80% obtained in 1998 Approved by the U.S. Food and Drug Administration for the treatment of moderate-severe Crohn’s disease and Crohn’s disease associated with fistulas. However, the efficacy of Infliximab can only be maintained for 2 to 3 months. After the treatment is stopped and the disease is easy to relapse, Infliximab is required to maintain the effect by intermittent intravenous injection. Repeated intravenous injection not only increases the patient’s financial burden, but also